Sri Maridi Biotech Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 05-12-2024
- Paid Up Capital ₹ 5.00 M
as on 05-12-2024
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2019
- Satisfied Charges ₹ 1.54 Cr
as on 05-12-2024
- Revenue %
(FY 2019)
- Ebitda
- Net Worth
- Total Assets 38.95%
(FY 2019)
About Sri Maridi Biotech
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company has closed loans amounting to ₹1.54 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ramachandrarao Doguparthi, Doguparthi Narayana, Konijeti Ayyappa, and One other member serve as directors at the Company.
- CIN/LLPIN
U01119AP2013PTC086973
- Company No.
086973
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Apr 2013
- Date of AGM
14 Jun 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Godavari, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sri Maridi Biotech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramachandrarao Doguparthi  | Director | 12-Apr-2013 | Current |
| Doguparthi Narayana | Director | 12-Apr-2013 | Current |
| Konijeti Ayyappa | Director | 12-Apr-2013 | Current |
| Patchipulusu Venkataramarao | Director | 12-Apr-2013 | Current |
Financial Performance of Sri Maridi Biotech.
Sri Maridi Biotech Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Sri Maridi Biotech?
In 2019, Sri Maridi Biotech had a promoter holding of 73.20% and a public holding of 26.80%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sri Vijay Durga Chits Private LimitedActive 9 years 4 monthsRamachandrarao Doguparthi and Patchipulusu Venkataramarao are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Syndicate Bank Creation Date: 30 Mar 2016 | ₹4.50 M | Satisfied |
Syndicate Bank Creation Date: 30 Mar 2015 | ₹1.09 Cr | Satisfied |
How Many Employees Work at Sri Maridi Biotech?
Unlock and access historical data on people associated with Sri Maridi Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sri Maridi Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sri Maridi Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
